查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712806

2025年全球放射性藥物市場報告

Radiopharmaceuticals Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年放射性藥物市場規模將快速成長。預計到 2029 年將成長至 105.9 億美元，複合年成長率為 11.8%。預測期內的成長是由於老年人口的增加、癌症和心血管疾病盛行率的上升、高額資本投資以及新產品的推出。預測期內的關鍵趨勢包括與其他公司合作以增加收益和提高產品品質、投資擴大工廠產能以滿足不斷成長的需求、投資新技術以滿足新興需求、探索In Silico模擬以獲得更合理和科學的方法、投資人工智慧以降低研發成本並縮短藥物開發時間、投資循環系統學技術以增加收益，以及採用特異性疾病的方法以便準確及時診斷癌症。

預計癌症和心血管疾病盛行率的上升將推動放射性藥物市場的需求。與傳統藥物相比，放射性藥物正成為一種更安全、更有效的治療選擇，標靶治療等優勢使放射科醫師受益於這些疾病的治療。癌症被公認為全球第二大死因，約佔六分之一的死因。例如，2024年4月，總部位於法國的專門機構國際癌症研究機構（IARC）報告稱，2022年全球將有約2,000萬例新發癌症病例和970萬例癌症相關死亡病例。到 2040 年，預計這一數字將上升至每年 2,990 萬例新病例和 1,530 萬例死亡病例。

由於個人化醫療需求的不斷增加，放射性藥物市場預計將經歷顯著成長。個人化醫療，也稱為精準醫療，是一種創新的醫療保健方法，根據每個患者的特徵來客製化醫療決策、治療、介入和藥物。將個人化醫療融入放射性藥物將提高影像和治療的精確度和準確性，使醫療保健提供者能夠提供更有針對性和更有效的治療。例如，2022年，美國食品藥物管理局（FDA）藥品評估與研究中心（CDER）核准了37個新分子實體（NME），其中12個（約34%）被個人化醫療聯盟（PMC）歸類為個人化醫療。因此，個人化醫療需求的不斷成長正在推動放射性藥物市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 世界放射性藥物PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球放射性藥物市場：成長率分析
  • 全球放射性藥物市場表現：規模與成長，2019-2024
  • 全球放射性藥物市場預測：2024-2029 年及 2034 年規模與成長
  • 全球放射性藥物總目標市場（TAM）

第6章市場區隔

  • 全球放射性藥物市場類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 診斷
  • 治療
  • 全球放射性藥物市場：依應用、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 腫瘤學
  • 心臟病學
  • 胃腸病學
  • 神經內分泌學
  • 肌肉骨骼
  • 呼吸系統
  • 腎臟病學
  • 其他用途
  • 全球放射性藥物市場：按最終用戶、績效和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院及門診手術中心
  • 診斷中心
  • 癌症研究所
  • 全球放射性藥物市場，診斷細分，按類型、績效和預測，2019-2024 年、2024-2029 年、2034 年
  • 正子斷層掃描（PET）放射性藥物
  • 單光子發射電腦斷層掃描（SPECT）放射性藥物
  • 全球放射性藥物市場、治療細分、按類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • α發射體
  • BETA射線發射器
  • 放射線治療

第7章 區域和國家分析

  • 全球放射性藥物市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球放射性藥物市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 放射性藥物市場：競爭格局
  • 放射性藥物市場：公司簡介
    • Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • General Electric Company（GE）Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • IBA Group
  • Bayer AG
  • Lantheus Medical Imaging Inc.
  • Bracco Imaging SpA
  • Eckert & Ziegler
  • Nihon Medi-Physics Co. Ltd.
  • Fujifilm Corporation
  • ANSTO
  • Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • Bracco Imaging SpA.
  • Canon Inc.
  • China Isotope & Radiation Corporation（CIRC）
  • Alliance Medical
  • Advanced Accelerator Applications
  • JSC Isotope

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年放射性藥物市場：提供新機會的國家
  • 2029年放射性藥物市場：細分市場將帶來新機會
  • 2029年放射性藥物市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r33021

Radiopharmaceuticals, also known as radioactive medications, are substances used for the diagnosis or treatment of diseases, including cancer, and contain a radioactive material. These medications are employed in various medical procedures to identify specific illnesses or detect medical issues. Patients may receive radiopharmaceuticals through different administration methods, such as injection, oral ingestion, or application into the eye or bladder.

Radiopharmaceuticals can be broadly categorized into diagnostic, therapeutic, and other types. The process of delivering radioactive atoms to targets associated with tumors is known as radiopharmaceutical therapy. These medications find applications in fields such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others. Hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and similar healthcare facilities commonly utilize radiopharmaceuticals for various medical purposes.

The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radiopharmaceuticals market size has grown steadily in recent years. It will grow from $6.46 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.

The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $10.59 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing geriatric population, increasing prevalence of cancer and cardiovascular diseases, high capital investments, and new product launches. Major trends in the forecast period include collaborating with other companies to boost revenues and improve product quality, investing in plant capacity expansions to cater to the increasing demand, investing in new technologies to meet the emerging demands, explore in silico modeling for a more rational and scientific approach, invest in AI to reduce R&D costs and save drug development time, invest in technologies catering to cardiology to boost revenues and accept disease-specific approaches for accurate and timely diagnosis of cancer.

The rising prevalence of cancer and cardiovascular diseases is expected to drive demand for the radiopharmaceuticals market. Radiopharmaceuticals are becoming a safe and effective therapeutic option compared to conventional medicines, offering advantages such as targeted therapy that benefits radiologists in treating these conditions. Cancer is recognized as the second leading cause of death globally, accounting for approximately 1 in 6 deaths. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a France-based specialized agency, reported that in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide. By 2040, these figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually.

The radiopharmaceuticals market is anticipated to experience significant growth, driven by the increasing demand for personalized medicine. Personalized medicine, also known as precision medicine, is an innovative approach to medical care that tailors medical decisions, treatments, interventions, and drug therapies to the unique characteristics of each patient. Integrating personalized medicine into radiopharmaceuticals enhances the precision and accuracy of imaging and therapy, enabling healthcare providers to deliver more targeted and effective care. For example, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34%, or 12 of them, classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing demand for personalized medicine is thus a driving force behind the growth of the radiopharmaceuticals market.

Several companies in the radiopharmaceuticals market are adopting strategic initiatives such as opening new manufacturing facilities and expanding plant capacity, gaining significant popularity. ITM Isotopen Technologien Munchen AG (ITM), for instance, launched a new manufacturing facility in the Munich area to increase the production capacity of high-purity (n.c.a.) Lutetium-177 and no-carrier-added (n.c.a.) Lutetium-177-containing radiopharmaceuticals. This move aims to meet the high demand for quality medical isotopes for precision oncology worldwide.

Major players in the radiopharmaceuticals market are forming partnerships to enhance their market profitability. In June 2023, the University of Pittsburgh Medical Center partnered with PharmaLogic Holdings Corporation to produce new radiopharmaceuticals at a Pittsburgh facility. This collaboration enables patients and professionals in the UPMC vicinity to access innovative diagnostic and therapeutic drugs that are not currently available. The non-exclusive agreement outlines the conversion of experimental radiopharmaceuticals into therapeutically useful medications.

In January 2024, Eli Lilly, a US-based pharmaceutical company, completed its acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to enhance its capabilities in the emerging field of radioligand therapies, which aim to make significant advancements in cancer treatment. Point Biopharma specializes in radiopharmaceuticals, complementing Lilly's existing oncology portfolio and promising to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for various cancers.

Major companies operating in the radiopharmaceuticals market include Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, UJV Rez, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacybapy-Monrol Nuclear Products, NTP Radioisotopes.

North America was the largest region in the global radiopharmaceuticals market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceuticals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radiopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The radiopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Diagnostic, Therapeutic
  • 2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
  • 3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
  • Subsegments:
  • 1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals; Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 2) By Therapeutic: Alpha Emitters; Beta Emitters; Brachytherapy
  • Companies Mentioned: Cardinal Health; Curium Pharma; Siemens Healthineers AG; Novartis AG; General Electric Company (GE)
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radiopharmaceuticals Market Characteristics

3. Radiopharmaceuticals Market Trends And Strategies

4. Radiopharmaceuticals Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Radiopharmaceuticals Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Radiopharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Radiopharmaceuticals Market Growth Rate Analysis
  • 5.4. Global Radiopharmaceuticals Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Radiopharmaceuticals Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Radiopharmaceuticals Total Addressable Market (TAM)

6. Radiopharmaceuticals Market Segmentation

  • 6.1. Global Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostic
  • Therapeutic
  • 6.2. Global Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Musculoskeletal
  • Respiratory
  • Nephrology
  • Other Applications
  • 6.3. Global Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Ambulatory Surgical Centers
  • Diagnostic Centers
  • Cancer Research Institutes
  • 6.4. Global Radiopharmaceuticals Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Positron Emission Tomography (PET) Radiopharmaceuticals
  • Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 6.5. Global Radiopharmaceuticals Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Emitters
  • Beta Emitters
  • Brachytherapy

7. Radiopharmaceuticals Market Regional And Country Analysis

  • 7.1. Global Radiopharmaceuticals Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Radiopharmaceuticals Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radiopharmaceuticals Market

  • 8.1. Asia-Pacific Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radiopharmaceuticals Market

  • 9.1. China Radiopharmaceuticals Market Overview
  • 9.2. China Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radiopharmaceuticals Market

  • 10.1. India Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radiopharmaceuticals Market

  • 11.1. Japan Radiopharmaceuticals Market Overview
  • 11.2. Japan Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radiopharmaceuticals Market

  • 12.1. Australia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radiopharmaceuticals Market

  • 13.1. Indonesia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radiopharmaceuticals Market

  • 14.1. South Korea Radiopharmaceuticals Market Overview
  • 14.2. South Korea Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radiopharmaceuticals Market

  • 15.1. Western Europe Radiopharmaceuticals Market Overview
  • 15.2. Western Europe Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radiopharmaceuticals Market

  • 16.1. UK Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radiopharmaceuticals Market

  • 17.1. Germany Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radiopharmaceuticals Market

  • 18.1. France Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radiopharmaceuticals Market

  • 19.1. Italy Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radiopharmaceuticals Market

  • 20.1. Spain Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radiopharmaceuticals Market

  • 21.1. Eastern Europe Radiopharmaceuticals Market Overview
  • 21.2. Eastern Europe Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radiopharmaceuticals Market

  • 22.1. Russia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radiopharmaceuticals Market

  • 23.1. North America Radiopharmaceuticals Market Overview
  • 23.2. North America Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radiopharmaceuticals Market

  • 24.1. USA Radiopharmaceuticals Market Overview
  • 24.2. USA Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radiopharmaceuticals Market

  • 25.1. Canada Radiopharmaceuticals Market Overview
  • 25.2. Canada Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radiopharmaceuticals Market

  • 26.1. South America Radiopharmaceuticals Market Overview
  • 26.2. South America Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radiopharmaceuticals Market

  • 27.1. Brazil Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radiopharmaceuticals Market

  • 28.1. Middle East Radiopharmaceuticals Market Overview
  • 28.2. Middle East Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radiopharmaceuticals Market

  • 29.1. Africa Radiopharmaceuticals Market Overview
  • 29.2. Africa Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radiopharmaceuticals Market Competitive Landscape And Company Profiles

  • 30.1. Radiopharmaceuticals Market Competitive Landscape
  • 30.2. Radiopharmaceuticals Market Company Profiles
    • 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. General Electric Company (GE) Overview, Products and Services, Strategy and Financial Analysis

31. Radiopharmaceuticals Market Other Major And Innovative Companies

  • 31.1. IBA Group
  • 31.2. Bayer AG
  • 31.3. Lantheus Medical Imaging Inc.
  • 31.4. Bracco Imaging S.p.A.
  • 31.5. Eckert & Ziegler
  • 31.6. Nihon Medi-Physics Co. Ltd.
  • 31.7. Fujifilm Corporation
  • 31.8. ANSTO
  • 31.9. Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • 31.10. Bracco Imaging SpA.
  • 31.11. Canon Inc.
  • 31.12. China Isotope & Radiation Corporation (CIRC)
  • 31.13. Alliance Medical
  • 31.14. Advanced Accelerator Applications
  • 31.15. JSC Isotope

32. Global Radiopharmaceuticals Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radiopharmaceuticals Market

34. Recent Developments In The Radiopharmaceuticals Market

35. Radiopharmaceuticals Market High Potential Countries, Segments and Strategies

  • 35.1 Radiopharmaceuticals Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Radiopharmaceuticals Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Radiopharmaceuticals Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer